Schonfeld Strategic Advisors’s Bicara Therapeutics BCAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$442K Buy
+23,752
New +$595K ﹤0.01% 2026
2025
Q4
– Sell
-504,085
Closed -$7.96M – 2713
2025
Q3
$7.96M Buy
504,085
+241,334
+92% +$2.7M 0.05% 422
2025
Q2
$2.44M Sell
262,751
-103,213
-28% -$1.23M 0.02% 876
2025
Q1
$4.77M Buy
+365,964
New +$4.86M 0.03% 541

Other funds holding BCAX

Schonfeld Strategic Advisors's BCAX Position: Q3 2026 in Review

Schonfeld Strategic Advisors opened a new position in Bicara Therapeutics (BCAX) in Q3 2026: 23,752 shares worth $442K. The stake represents ﹤0.01% of the portfolio and ranks #2026 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in BCAX as recently as Q3 2025.

Schonfeld Strategic Advisors first reported a position in BCAX in Q1 2025 and has held it in 4 quarters since. The position peaked at $7.96M in Q3 2025. 169 funds tracked by Wall St. Rank hold BCAX as of Q3 2026.

  • Schonfeld Strategic Advisors held 23,752 shares of Bicara Therapeutics worth $442K as of Q3 2026.
  • Bicara Therapeutics was a new Schonfeld Strategic Advisors position in Q3 2026.
  • Bicara Therapeutics made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q3 2026, its #2026 holding.
  • Schonfeld Strategic Advisors first reported a position in Bicara Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • Schonfeld Strategic Advisors's Bicara Therapeutics position peaked at $7.96M in Q3 2025.
  • 169 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q3 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.